Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

ARQT
Arcutis Biotherapeutics, Inc. Common Stock
stock NASDAQ

At Close
Jul 30, 2026 3:59:53 PM EDT
27.99USD+0.413%(+0.12)1,265,872
23.87Bid   33.98Ask   10.11Spread
Pre-market
Jul 30, 2026 8:30:30 AM EDT
27.94USD+0.251%(+0.07)3,008
After-hours
Jul 30, 2026 4:17:30 PM EDT
28.00USD+0.054%(+0.01)285
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Dec 23, 2021
10:18AM EST  Arcutis Secures $225M Debt Financing To Fund Potential Launch Of Roflumilast   Benzinga
08:51AM EST  Arcutis' Roflumilast Cream For Psoriasis Goes Under FDA Review   Benzinga
08:01AM EST  Arcutis Biotherapeutics Reports Secured $225M In Non-Dilutive Financing From SLR Capital Partners   Benzinga
08:00AM EST  Arcutis Biotherapeutics Secures $225 Million in Non-Dilutive Debt   GlobeNewswire Inc
07:29AM EST  The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review   Benzinga
Dec 22, 2021
04:02PM EST  Arcutis Biotherapeutics Announces FDA Has Accepted The Co.'s New Drug Application For Roflumilast Cream For Adults And Adolescents With Plaque Psoriasis   Benzinga
04:01PM EST  -- FDA has set a target action date of July 29, 2022 -- NDA supported by positive efficacy data from the pivotal Phase 3 DERMIS 1 and DERMIS 2 clinical studies, as well as results from the long-term safety study -- If approved, roflumilast cream would be the first and only topical PDE4 inhibitor for psoriasis   GlobeNewswire Inc
Dec 16, 2021
08:00AM EST  Arcutis Appoints Mas Matsuda as General Counsel and Corporate   GlobeNewswire Inc
Dec 13, 2021
08:00AM EST  -- Data presented at Revolutionizing Atopic Dermatitis (RAD) Conference -- Vehicle tested was comparable to the moisturizing cream based on primary endpoint of change in transepidermal water loss (TEWL) from baseline at Day 15 -- Data provide additional support for ongoing studies of investigational product roflumilast cream in atopic dermatitis   GlobeNewswire Inc
Nov 19, 2021
08:54AM EST  Morgan Stanley Maintains Overweight on Arcutis Biotherapeutics, Lowers Price Target to $35   Benzinga
Nov 10, 2021
08:02AM EST  Arcutis Biotherapeutics, Inc.(Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions, today announced that Arcutis management will participate in an upcoming investor conference in November.   GlobeNewswire Inc
Nov 5, 2021
09:27AM EDT  Arcutis Biotherapeutics Q3 EPS $(1.14) Down From $(1.01) YoY   Benzinga
Oct 4, 2021
08:02AM EDT  Arcutis Submits Topical Roflumilast Cream New Drug Application To FDA For Treatment Of Adults And Adolescents With Plaque Psoriasis   Benzinga
08:00AM EDT  Arcutis Submits Topical Roflumilast Cream New Drug Application to   GlobeNewswire Inc
Sep 30, 2021
08:30AM EDT  New Data Highlighting Itch Reduction with Topical Roflumilast in   GlobeNewswire Inc
07:43AM EDT  The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug   Benzinga
Sep 28, 2021
04:08PM EDT  Arcutis Biotherapeutics Highlights New Patent Issued By US Patent & Trademark Office 'covering its invention for improving delivery and extending half-life of both the cream and foam formulations of topical roflumilast'   Benzinga
04:05PM EDT  Arcutis Expands Patent Portfolio with Roflumilast Pharmacokinetics   GlobeNewswire Inc
06:07AM EDT  Arcutis Biotherapeutics On September 22, Entered Supply And Manufacturing Agreement With DPT Laboratories, Ltd.   Benzinga
Sep 27, 2021
08:10AM EDT  CORRECTION: Arcutis Biotherapeutics Ticker Is 'ARQT'   Benzinga
08:10AM EDT  Arcutis Biotherapeutics to Present Data At European Academy of Dermatology and Venereology (EADV) Congress.   Benzinga
08:05AM EDT  New Topical Roflumilast Data Presented at the European Academy of   GlobeNewswire Inc
Sep 9, 2021
04:10PM EDT  Arcutis Biotherapeutics, Inc.(Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology to address the urgent needs of patients living with immune-mediated dermatological diseases and conditions, today announced that Arcutis management will participate in two upcoming investor conferences in September.   GlobeNewswire Inc
Sep 2, 2021
04:10PM EDT  Arcutis Announces Appointment of Keith Leonard to Board of Directors   GlobeNewswire Inc
Aug 31, 2021
11:14AM EDT  Arcutis Biotherapeutics Sponsored Study Titled 'A Randomized tRial Employing topiCal roflumilasT Foam to Treat Scalp Psoriasis (ARRECTOR) (ARRECTOR)' Posted To ClinicalTrials.gov; Study Not Yet Recruiting   Benzinga
Aug 25, 2021
08:05AM EDT  Arcutis Enrolls First Patient In Phase 3 Clinical Trial Of ARQ-154 As A Potential Treatment For Scalp And Body Psoriasis   RTTNews
08:02AM EDT  Arcutis Enrolls First Patient In Phase 3 Clinical Trial Of Topical Roflumilast Foam (ARQ-154) As A Potential Treatment For Scalp And Body Psoriasis   Benzinga
08:00AM EDT  -- Topical roflumilast potential Best-in-Class topical PDE4 inhibitor -- Scalp and body psoriasis affects more than 8 million patients in the U.S.   GlobeNewswire Inc
Aug 23, 2021
08:12AM EDT  Arcutis Biotherapeutics Names Bruce Binkowitz VP Of Biometrics   RTTNews
08:00AM EDT  Bruce Binkowitz Joins Arcutis as Vice President of Biometrics   GlobeNewswire Inc
Aug 5, 2021
05:38PM EDT  Arcutis Biotherapeutics Q2 EPS $(0.84) Up From $(0.94) YoY   Benzinga
Aug 2, 2021
04:05PM EDT  -- Eric McIntyre joins as Head of Investor Relations -- Amanda Sheldon joins as Head of Corporate Communications   GlobeNewswire Inc
Jul 21, 2021
08:00AM EDT  -- The majority of patients with psoriasis have mild or moderate levels of disease -- The new method, PASI-high discrimination (PASI-HD), is designed for use in clinical trials evaluating novel topical treatment options for psoriasis -- Details of new approach published in Dermatology and Therapy   GlobeNewswire Inc
Jul 16, 2021
08:31AM EDT  Morgan Stanley Maintains Overweight on Arcutis Biotherapeutics, Lowers Price Target to $50   Benzinga
Jul 12, 2021
08:11AM EDT  Arcutis Announces First Patient Enrolled in Phase 3 Clinical Trial of Topical Roflumilast Foam (ARQ-154) as a Potential Treatment for Seborrheic Dermatitis   Benzinga
08:00AM EDT  -- Topical roflumilast potential Best-in-Class topical PDE4 inhibitor -- Seborrheic dermatitis affects 10 million patients in the U.S. -- Potential first new topical treatment for seborrheic dermatitis in decades -- The Company anticipates topline data in the second or third quarter of 2022   GlobeNewswire Inc
Jul 1, 2021
12:04PM EDT  Arcutis Stops ARQ-252 Vitiligo Trial After Formulation-Related Observations In Chronic Hand Eczema Study   Benzinga
07:12AM EDT  Arcutis Biotherapeutics, Inc. (ARQT), a medical dermatology company, announced Thursday its decision to terminate the recently initiated Phase 2a clinical trial evaluating ARQ-252 cream as a potential treatment for vitiligo (ARQ-252-213).   RTTNews
06:26AM EDT  Arcutis Decides To Terminate Phase 2a Trial Evaluating ARQ-252 As A Potential Treatment For Vitiligo   RTTNews
06:10AM EDT  Arcutis Provides Update on Phase 2a Clinical Trial Evaluating ARQ-252 Cream as a Potential Treatment for Vitiligo; Terminates Trial   Benzinga
06:00AM EDT  -- Formulation-related observations from ARQ-252 trial in chronic hand eczema informed early termination of Phase 2a ARQ-252 trial in vitiligo -- Company progressing new formulation with goal of greater drug delivery to targets in the skin   GlobeNewswire Inc
Jun 30, 2021
10:56AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For June 30, 2021   Benzinga
05:02AM EDT  Mizuho Initiates Coverage On Arcutis Biotherapeutics with Buy Rating, Announces Price Target of $58   Benzinga
Jun 23, 2021
08:00AM EDT  Greg Sukay Joins Arcutis as Vice President of Manufacturing and   GlobeNewswire Inc
Jun 9, 2021
04:01PM EDT  Arcutis Announces Appointment of Sue-Jean Lin to Board of Directors   GlobeNewswire Inc
Jun 1, 2021
07:42AM EDT  Arcutis Biotherapeutics Names Rajvir Madan First Chief Digital And Information Officer   RTTNews
07:30AM EDT  Rajvir Madan Joins Arcutis as Chief Digital and Information Officer   GlobeNewswire Inc
May 27, 2021
10:02AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For May 27, 2021   Benzinga
07:55AM EDT  Morgan Stanley Initiates Coverage On Arcutis Biotherapeutics with Overweight Rating, Announces Price Target of $52   Benzinga
May 6, 2021
08:30AM EDT  Arcutis Biotherapeutics Showcases Pivotal DERMIS-1 and -2 Phase 3   GlobeNewswire Inc
May 4, 2021
05:29PM EDT  Arcutis Biotherapeutics Q1 EPS $(0.76) Up From $(1.15) YoY   Benzinga
May 3, 2021
04:40PM EDT  Arcutis Biotherapeutics To Present New Roflumilast Cream Phase 3 Data At The European Academy of Dermatology and Venereology Spring Symposium May 6-7, 2021   Benzinga
04:09PM EDT  Presentation will highlight efficacy and safety data from the DERMIS-1 and DERMIS-2 pivotal Phase 3 studies evaluating roflumilast cream (ARQ-151) as a potential topical once-daily treatment for chronic plaque psoriasis   GlobeNewswire Inc
Apr 28, 2021
04:30PM EDT  Arcutis to Present at the 2021 Truist Securities Life Sciences Summit   GlobeNewswire Inc
Apr 23, 2021
11:05AM EDT  Arcutis' Roflumilast Foam Improves Scalp, Body Psoriasis As Early As Two Weeks After Treatment Initiation   Benzinga
10:03AM EDT  Arcutis Biotherapeutics Showcases New Roflumilast Data in Psoriasis and Seborrheic Dermatitis at American Academy of Dermatology Virtual Meeting Experience 2021   Benzinga
10:01AM EDT  Arcutis Biotherapeutics Showcases New Roflumilast Data in   GlobeNewswire Inc
Apr 19, 2021
09:05AM EDT  Arcutis Biotherapeutics to Present New Roflumilast Data at The   GlobeNewswire Inc
Apr 12, 2021
09:25AM EDT  Arcutis Initiates Phase 3 Clinical TrialOf Topical Roflumilast Cream As Potential Treatment For Atopic Dermatitis In Pediatric Patients Between The Ages Of Two AArcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a late-stage biopharmaceutical compand Five Years   Benzinga
09:05AM EDT  -- Roflumilast cream potential Best in Class topical PDE4 inhibitor -- Atopic dermatitis affects approximately 19 million patients in the U.S. -- The Company anticipates topline data in the second half of 2022   GlobeNewswire Inc
Mar 26, 2021
09:03AM EDT  Arcutis Announces Scott Burrows Will Become CFO   Benzinga
09:00AM EDT  -- Scott Burrows to succeed John Smither as Chief Financial Officer (CFO) upon Mr. Smithers retirement -- Corey Padovano named Vice President of Sales -- Sean Brugger joins as Executive Director of Field Medical Affairs   GlobeNewswire Inc
Mar 18, 2021
09:09AM EDT  Arcutis Announces First Patient Enrolled In Phase 2a Clinical Trial Evaluating ARQ-252 As A Potential Treatment For Vitiligo   Benzinga
09:05AM EDT  -- ARQ-252 is a potent and highly selective topical JAK1 inhibitor offering potential safety advantages over less selective JAK inhibitors -- Topline data anticipated second half 2023 -- Vitiligo affects approximately 1.3 million patients in the U.S.   GlobeNewswire Inc
Mar 17, 2021
04:08PM EDT  Arcutis Biotherapeutics to Showcase Long-term Safety, Efficacy, and Patient-Reported Outcomes of Roflumilast Cream for Chronic Plaque Psoriasis at Innovations in Dermatology: Virtual Spring Conference 2021   Benzinga
04:05PM EDT  Arcutis Biotherapeutics to Showcase Long-term Safety, Efficacy,   GlobeNewswire Inc
Feb 18, 2021
09:00AM EST  Courtney Barton Joins Arcutis as Chief Compliance Officer and   GlobeNewswire Inc
Feb 16, 2021
04:13PM EST  Arcutis Biotherapeutics Q4 EPS $(0.79) Up From $(6.13) YoY   Benzinga
04:05PM EST  Arcutis Announces Fourth Quarter and Full Year 2020 Financial   GlobeNewswire Inc
09:00AM EST  Arcutis Biotherapeutics Announces Closing of   GlobeNewswire Inc
Feb 3, 2021
06:57AM EST  Arcutis Biotherapeutics Raises $192.5 Million In Upsized Offering   Benzinga
Feb 2, 2021
08:54PM EST  Arcutis Biotherapeutics Prices Upsized Public Offering Of 5.50 Mln Shares Of Its Common Stock At $35.00/shr   RTTNews
08:03PM EST  Arcutis Biotherapeutics Announces Pricing of Upsized Public   GlobeNewswire Inc
11:16AM EST  Truist Securities Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $48   Benzinga
08:05AM EST  The Daily Biotech Pulse: Vertex, Pfizer Earnings, Tiziana COVID-19 Vaccine Data, Decision Day For Mallinckrodt's Burn Treatment   Benzinga
Feb 1, 2021
04:09PM EST  Arcutis Biotherapeutics Announces$150M Proposed Public Offering Of Common Stock   Benzinga
04:09PM EST  Arcutis Biotherapeutics Announces Proposed Public Offering of   GlobeNewswire Inc
10:11AM EST  Cowen & Co. Maintains Outperform on Arcutis Biotherapeutics, Raises Price Target to $80   Benzinga
07:37AM EST  Arcutis Announces Positive Topline Results From Pivotal DERMIS-1 And -2 Phase 3 Trials Of ARQ-151 In Plaque Psoriasis   RTTNews
07:30AM EST  Arcutis Announces Positive Topline Results from Pivotal DERMIS-1   GlobeNewswire Inc
Jan 20, 2021
09:03AM EST  Arcutis Reports Will Advance Topical Roflumilast Foam Into Phase 3 Development For Treatment Of Seborrheic Dermatitis   Benzinga
09:00AM EST  -- Phase 3 development to consist of single pivotal trial -- Previously reported data demonstrated that roflumilast foam provided statistically significant improvement and a favorable safety and tolerability profile -- Roflumilast foam potential Best in Class topical PDE4 inhibitor -- Seborrheic dermatitis affects 10 million U.S. patients   GlobeNewswire Inc
Jan 13, 2021
09:01AM EST  Arcutis Initiates Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast Cream (ARQ-151) As A Potential Treatment For Atopic Dermatitis   Benzinga
09:00AM EST  -- Roflumilast cream potential Best in Class topical PDE4 inhibitor -- Atopic dermatitis affects approximately 19 million patients in the U.S. -- The Company anticipates topline data in the second half of 2022   GlobeNewswire Inc
Jan 11, 2021
09:00AM EST  Matthew Moore Joins Arcutis as Chief Business Officer   GlobeNewswire Inc
Dec 21, 2020
09:27AM EST  Arcutis Biotherapeutics Added to Nasdaq Biotechnology Index   Benzinga
Dec 9, 2020
09:06AM EST  Arcutis Biotherapeutics Says Pipeline Has Potential To Generate Sales Of ~$3B-$8B By 2030 In U.S. Market Alone   Benzinga
09:00AM EST  Arcutis Highlights Advanced Pipeline & Unique Immuno-Dermatology   GlobeNewswire Inc
Dec 7, 2020
09:05AM EST  Arcutis Announces Last Patient Completes Final Study Visit In DERMIS-1 And DERMIS-2 Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 (Topical Roflumilast Cream) As A Potential Treatment For Plaque Psoriasis   Benzinga
09:00AM EST  -- Phase 3 trials topline data anticipated in the first quarter of 2021 and potential New Drug Application (NDA) submission anticipated by the end of 2021 -- Roflumilast cream potential Best in Class topical PDE4 inhibitor -- Plaque psoriasis affects approximately 8.6 million patients in the U.S.   GlobeNewswire Inc
Dec 2, 2020
04:05PM EST  Arcutis to Host Virtual Investor Day on Wednesday, December 9, 2020   GlobeNewswire Inc
Dec 1, 2020
04:11PM EST  Arcutis Biotherapeutics Announces Results From Phase 2 Long-Term Safety Study Evaluating ARQ-151 For Plaque Psoriasis; Says Demonstrated 'favorable safety and tolerability over 52 to 64 weeks of treatment'   Benzinga
04:05PM EST  Data from Long-Term Safety Study Support Chronic Use of   GlobeNewswire Inc
Nov 23, 2020
07:39AM EST  Arcutis Announces Results From Phase 2b Study of ARQ-154 as a Potential Treatment for Scalp and Body Psoriasis Demonstrated Statistically Significant Improvement On The Trial's Primary And Multiple Secondary Endpoints   Benzinga
07:30AM EST  Arcutis Announces Positive Topline Data from Phase 2b Study of   GlobeNewswire Inc
Nov 11, 2020
04:05PM EST  Arcutis Biotherapeutics to Present at the Stifel 2020 Virtual   GlobeNewswire Inc
Nov 9, 2020
06:01AM EST  Goldman Sachs Upgrades Arcutis Biotherapeutics to Buy, Announces $36 Price Target   Benzinga
Nov 5, 2020
04:51PM EST  Arcutis Biotherapeutics Q3 EPS $(1.01) Up From $(7.56) YoY   Benzinga
Nov 4, 2020
04:05PM EST  Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a medical dermatology company developing innovative treatments for patients with immune-mediated dermatological diseases and conditions, today announced that Terrie Curranhas been appointed to the Arcutis Board of Directors effective Nov. 2, 2020, and that Alexander Asam, Ph.D. has decided to step down from the Board.   GlobeNewswire Inc
Nov 2, 2020
09:04AM EST  Arcutis Biotherapeutics Highlights Presentation Of New Data From Phase 2 Studies Of ARQ-151 In Chronic Plaque Psoriasis, Atopic Dermatitis   Benzinga
09:00AM EST  Arcutis Biotherapeutics Presents New Positive Data from Phase 2   GlobeNewswire Inc
Oct 30, 2020
05:43AM EDT  Arcutis Biotherapeutics Announced it Will Present New Data from ARQ-151 Clinical Program at Three Global Dermatology Conferences   Benzinga
Oct 26, 2020
09:04AM EDT  Arcutis Completes Enrollment In Phase 1/2b Study Evaluating ARQ-252 In Chronic Hand Eczema   Benzinga
09:00AM EDT  -- ARQ-252 is a potent and highly selective topical JAK1 inhibitor offering potential safety advantages over less selective JAK inhibitors -- Hand eczema is the most common skin disease affecting the hands, impacting more than 8 million Americans -- Topline data now anticipated by mid-2021   GlobeNewswire Inc
Oct 8, 2020
10:14AM EDT  Arcutis Biotherapeutics shares are trading higher after Truist Securities initiated coverage on the stock with a Buy rating and a price target of $38 per share.   Benzinga
10:00AM EDT  Benzinga's Top Upgrades, Downgrades For October 8, 2020   Benzinga
08:24AM EDT  Truist Securities Initiates Coverage On Arcutis Biotherapeutics with Buy Rating, Announces Price Target of $38   Benzinga
06:28AM EDT  Arcutis Biotherapeutics Shares Move Higher Premarket; Hearing Truist Securities Starts With A Buy Rating And $38 Price Target   Benzinga
Oct 6, 2020
04:05PM EDT  Arcutis Biotherapeutics Announces Closing of Public Offering and   GlobeNewswire Inc
Oct 2, 2020
03:04PM EDT  Mid-Morning Market Update: Markets Open Lower; US Unemployment Rate Falls To 7.9% In September   Benzinga
09:57AM EDT  Shares of Arcutis Biotherapeutics, Inc. (ARQT) slipped nearly 15% on Friday morning. The company announced it has made a secondary offering with 4 million shares of its stock.   RTTNews
05:34AM EDT  Arcutis Biotherapeutics Priced 4M Share Public Offering and 1.4M Share Concurrent Private Placement of Common Stock @$25/Share   Benzinga
Oct 1, 2020
10:47PM EDT  Arcutis Biotherapeutics Announces Pricing of Public Offering and   GlobeNewswire Inc
Sep 29, 2020
04:52PM EDT  Arcutis Biotherapeutics Announces Proposed Public Offering of 4M Shares of Common Stock   Benzinga
04:51PM EDT  Arcutis Biotherapeutics Announces Proposed Public Offering and   GlobeNewswire Inc
08:02AM EDT  Arcutis Announces Roflumilast Foam Demonstrated Statistically Significant Improvement Over The Vehicle Foam On The Trial's Primary And Multiple Secondary Endpoints   Benzinga
08:00AM EDT  Arcutis Announces Positive Topline Data from Phase 2 Clinical   GlobeNewswire Inc
Sep 16, 2020
09:03AM EDT  Arcutis Completes Enrollment In DERMIS-1 And DERMIS-2 Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 As A Potential Treatment For Plaque Psoriasis; Topline Data Now Anticipated By End Of 2021   Benzinga
09:00AM EDT  -- Roflumilast cream potential Best in Class topical PDE4 inhibitor -- Plaque psoriasis affects approximately 8.6 million patients in the U.S. -- Phase 3 trials topline data now anticipated in the first quarter of 2021 and New Drug Application (NDA) submission anticipated by the end of 2021   GlobeNewswire Inc
Sep 15, 2020
09:00AM EDT  Arcutis to Present at the Cantor Fitzgerald Global Healthcare   GlobeNewswire Inc
Sep 8, 2020
09:01AM EDT  Arcutis Biotherapeutics To Accelerate ARQ-151 Into Phase 3 Trials For Treatment Of Atopic Dermatitis Following End-Of-Phase 2 Meeting With FDA   Benzinga
09:00AM EDT  Arcutis Biotherapeutics to Accelerate ARQ-151 (Topical Roflumilast   GlobeNewswire Inc
Aug 11, 2020
04:04PM EDT  Arcutis Biotherapeutics Q2 EPS $(0.94) Up From $(4.69) YoY   Benzinga
04:02PM EDT  Arcutis Announces Second Quarter 2020 Financial Results and   GlobeNewswire Inc
Aug 10, 2020
09:00AM EDT  Arcutis to Present at the Wedbush PacGrow Healthcare Conference   GlobeNewswire Inc
Aug 4, 2020
09:00AM EDT  Bethany Dudek Joins Arcutis as Vice President of Quality   GlobeNewswire Inc
Aug 3, 2020
09:21AM EDT  UPDATE: Arcutis Biotherapeutics Reports Phase 1/2a ARQ-151 Data Showed Significant Improvement In Signs, Symptoms Of Chronic Plaque Psoriasis; Co. Sees Topline Data From Phase 3 Trial In H1'21   Benzinga
09:11AM EDT  The Journal Of Drugs In Dermatology Publishes Results From Phase 1/2a Trial Of Arcutis' ARQ-151 For Treatment Of Chronic Plaque Psoriasis   Benzinga
09:00AM EDT  -- Data demonstrate potential Best in Class topical PDE4 inhibitor roflumilast significantly improves signs and symptoms of chronic plaque psoriasis -- Phase 3 topline data anticipated first half of 2021   GlobeNewswire Inc
Jul 31, 2020
09:04AM EDT  Preliminary Data From Long-Term Safety Study Support Chronic Use Of ARQ-151 As Potential Treatment For Plaque Psoriasis   Benzinga
09:00AM EDT  -- Once-daily roflumilast demonstrated favorable safety and tolerability over 52 to 64 weeks of treatment -- At 52 to 64 weeks of treatment, 44% of subjects had attained an IGA of clear or almost clear -- Preliminary data further support the potential of roflumilast as a novel, once-daily, chronic topical treatment for plaque psoriasis, including intertriginous psoriasis   GlobeNewswire Inc
Jul 27, 2020
09:00AM EDT  -- Experienced industry leader to head Arcutis clinical development programs -- Appointment aligns with Arcutis strategy of building a team with deep dermatology expertise -- Howard Welgus, M.D., FAAD to retire; elected to Arcutis Board of Directors   GlobeNewswire Inc
Jul 20, 2020
09:14AM EDT  Arcuits Enrolls Last Patient In Phase 2b Clinical Trial Evaluating ARQ-154 As Potential Treatment For Scalp Psoriasis   Benzinga
09:00AM EDT  -- Roflumilast foam potential Best in Class topical PDE4 inhibitor in foam formulation -- Scalp psoriasis affects more than 2.5 million U.S. patients -- Phase 2b topline data anticipated fourth quarter 2020   GlobeNewswire Inc
Jul 15, 2020
05:09PM EDT  Arcutis Biotherapeutics Highlights New England Journal Of Medicine Published Results From Phase 2b Trial Of Co.'s ARQ-151 For Treatment Of Chronic Plaque Psoriasis   Benzinga
05:07PM EDT  -- Data demonstrate potential Best in Class topical PDE4 inhibitor roflumilast significantly improves chronic plaque psoriasis -- Phase 3 topline data anticipated first half of 2021   GlobeNewswire Inc
Jul 13, 2020
09:03AM EDT  Arcutis Biotherapeutics Reports Initiation Of Patient Enrollment In Phase 2b Portion Of Phase 1/2b Study Of ARQ-252 In Chronic Hand Eczema; Sees Topline Data In H2'21   Benzinga
09:00AM EDT  -- ARQ-252 is a potent and highly selective topical JAK1 inhibitor offering potential safety advantages over less selective JAK inhibitors -- Company expects topline data in the second half of 2021   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC